Allotment results | Simcere Pharmacy-B (02410) 47.88% of IPO subscribers were successfully allotted at a final price of HKD 12.1
Tongyuan Kangyao Pharmaceutical-B (02410) placement ended.
On August 20th, the placement of Tongyuan Kangyao Pharmaceutical-B (02410) ended. The offer price was HK$12.1, and the final price was set at HK$12.1 per share, with each lot costing HK$6050.
For the public offering, there were 974 applicants, with a 47.88% allotment rate for one lot, and a subscription multiple of approximately 2.29 times. The number of international placement applicants was not disclosed, with a subscription multiple of approximately 1.01 times.
The number of international placement applicants was not disclosed, with an oversubscription multiple indicating moderate oversubscription.
Related Articles

China Securities Co.,Ltd.: Brain-Computer Interface Upgraded to a 15th Five-Year Plan Industrial Strategy; Upstream, Midstream, and Downstream Collaborate to Build a New Ecosystem of Human-Machine Integration

Russian court rules that Rio Tinto plc Sponsored ADR (RIO.US) must pay RUSAL (00468) approximately US$1.3 billion in damages; Mongolian OT copper mine interests may face enforcement

UBS Group AG: Maintains "Neutral" rating on Tesla, Inc. (TSLA.US), target price $385. AI narrative dominates the stock's pricing logic.
China Securities Co.,Ltd.: Brain-Computer Interface Upgraded to a 15th Five-Year Plan Industrial Strategy; Upstream, Midstream, and Downstream Collaborate to Build a New Ecosystem of Human-Machine Integration

Russian court rules that Rio Tinto plc Sponsored ADR (RIO.US) must pay RUSAL (00468) approximately US$1.3 billion in damages; Mongolian OT copper mine interests may face enforcement

UBS Group AG: Maintains "Neutral" rating on Tesla, Inc. (TSLA.US), target price $385. AI narrative dominates the stock's pricing logic.






